BioSpace News Archive

Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO (Contract Commercial Organization), today announced that Chief Executive Officer Alistair Macdonald and Chief Financial Officer Jason Meggs are scheduled to present at two upcoming investor conferences: Jefferies Virtual Healthcare Conference on Wednesday, June 3, 2020, at 9:30 a.m. E

- Foundation celebrates second regulatory approval from funded portfolio with FDA decision on Kynmobi for “off” time in Parkinson’s disease - Approval is proof of impact for MJFF’s unique investment strategy that “de-risks” early-stage projects for larger partners [22-May-2020] NEW YORK , May 22, 2020 /PRNewswire/ -- The Michael J. Fox Fo

Cerner Corporation (Nasdaq: CERN), a global health care technology company, today announced that its Board of Directors declared a cash dividend to stockholders of $0.18 per issued and outstanding share. The cash dividend will be payable on July 17, 2020, to shareholders of record as of the close of business on June 5, 2020. Cerner intends to pay regular quarterly cash dividends, with future declarations subject to approval by its Board

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”) today announced the closing of its previously announced public offering and concurrent registered direct offering (the “Offerings”) for gross proceeds of approximately $43.7 million, which includes the full exercise of the underwriters’ option to purchase additional shares.

Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that their COVID-19 vaccine program has reached a milestone with the manufacturing of 33 Ii-Key-SARS-CoV-2 peptides using antigenic epitopes predicted by computational vaccinology algorithms.

Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Elanco Animal Health Incorporated (“Elanco” or “the Company”) (NYSE: ELAN) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Elanco securities between January 10, 2020 a

Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based protein expres

Smart inhalers are increasingly becoming the preferred course of managing and treating respiratory diseases.

Transparency Market Research has published a new report titled, ‘Ophthalmic Ultrasound Systems Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027’.

A report by Transparency Market Research states that the global gastrointestinal drugs market is expected to witness a robust growth during the tenure of 2016 to 2024.